ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Pepperstone

Trade Now

Pepperstone
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P ASX 200
7,770.00
0.27%
S&P ASX All Technology
3,432.50
-0.26%
Brent Oil
69.925
-1.08%
US Dollar vs AUD
1.59036
0.61%
Bitcoin
81,057.19
-3.13%
Pepperstone
Advertisement
Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Iterum Therapeutics PLC (ITRM)

  7. Iterum Therapeutics PLC (ITRM) News

ITRM

Iterum Therapeutics (ITRM)

Iterum Therapeutics PLC
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:ITRM
DateTimeSourceHeadlineSymbolCompany
10/03/202523:35Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ITRMIterum Therapeutics PLC
20/02/202516:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:ITRMIterum Therapeutics PLC
15/02/202508:49Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ITRMIterum Therapeutics PLC
08/02/202508:33Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:ITRMIterum Therapeutics PLC
07/02/202523:30Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:ITRMIterum Therapeutics PLC
07/02/202523:15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ITRMIterum Therapeutics PLC
07/02/202523:00GlobeNewswire Inc.Iterum Therapeutics Reports Fourth Quarter and Full Year 2024 Financial ResultsNASDAQ:ITRMIterum Therapeutics PLC
01/02/202500:00GlobeNewswire Inc.Iterum Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results on February 7, 2025NASDAQ:ITRMIterum Therapeutics PLC
11/12/202422:30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ITRMIterum Therapeutics PLC
10/12/202423:04Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:ITRMIterum Therapeutics PLC
22/11/202401:15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ITRMIterum Therapeutics PLC
22/11/202400:30GlobeNewswire Inc.Iterum Therapeutics Regains Full Nasdaq ComplianceNASDAQ:ITRMIterum Therapeutics PLC
14/11/202423:30Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ITRMIterum Therapeutics PLC
14/11/202423:15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ITRMIterum Therapeutics PLC
14/11/202423:00GlobeNewswire Inc.Iterum Therapeutics Reports Third Quarter 2024 Financial ResultsNASDAQ:ITRMIterum Therapeutics PLC
12/11/202400:00GlobeNewswire Inc.Iterum Therapeutics to Report Third Quarter 2024 Financial Results on November 14, 2024NASDAQ:ITRMIterum Therapeutics PLC
02/11/202408:10Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ITRMIterum Therapeutics PLC
30/10/202421:24Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:ITRMIterum Therapeutics PLC
28/10/202421:06Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:ITRMIterum Therapeutics PLC
28/10/202420:00PR Newswire (US)Iterum Therapeutics to Host Morning Conference Call on U.S. FDA Approval of ORLYNVAH™ (Oral Sulopenem) for the Treatment of Uncomplicated Urinary Tract InfectionsNASDAQ:ITRMIterum Therapeutics PLC
26/10/202402:20Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ITRMIterum Therapeutics PLC
26/10/202402:03GlobeNewswire Inc.Iterum Therapeutics Receives U.S. FDA Approval of ORLYNVAH™ (Oral Sulopenem) for the Treatment of Uncomplicated Urinary Tract InfectionsNASDAQ:ITRMIterum Therapeutics PLC
15/10/202423:00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ITRMIterum Therapeutics PLC
12/10/202407:01Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:ITRMIterum Therapeutics PLC
10/10/202423:30GlobeNewswire Inc.Iterum Therapeutics to Present Data at IDWeek 2024NASDAQ:ITRMIterum Therapeutics PLC
10/10/202408:00GlobeNewswire Inc.Iterum Therapeutics to Participate at the 2024 Maxim Healthcare Virtual SummitNASDAQ:ITRMIterum Therapeutics PLC
09/10/202400:15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ITRMIterum Therapeutics PLC
05/10/202407:20Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ITRMIterum Therapeutics PLC
01/10/202406:15Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:ITRMIterum Therapeutics PLC
30/09/202421:30Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:ITRMIterum Therapeutics PLC
 Showing the most relevant articles for your search:NASDAQ:ITRM

Your Recent History

BIT
UC5CEJ
Unicredit Bank
BIT
P135U7
BNP PARIBAS ISSUANCE
BIT
I09191
Intesa Sanpaolo
AQEU
BNBB
National Bank of Belgium
BIT
P1NYZ1
BNP Paribas Issuance
BIT
UB8PE6
Unicredit Bank
BIT
I10490
IT0005616351 20250303 9
BIT
Q00119
Leonteq Securities
BIT
P1TIU2
BNP Paribas Issuance
DBI
DL39
LevDax X5 AR Price Retur...
USOTC
LSAWS
Landa App (GM)
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Australia
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2025 ADVFN PLC - All Rights Reserved

Go Ad-Free

Subscribe to Ad free and enjoy an ad-free experience

No Ads

Try Now

Keep the Ads